$35.29
0.76%
Nasdaq, Nov 28, 10:00 pm CET

Harmony Biosciences Holdings Stock price

$35.29
+5.65 19.06% 1M
+1.57 4.66% 6M
+0.88 2.56% YTD
-0.46 1.29% 1Y
-22.60 39.04% 3Y
-7.96 18.40% 5Y
-1.72 4.65% 10Y
-1.72 4.65% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.27 0.76%

New AI Insights on Harmony Biosciences Holdings Insights AI Insights on Harmony Biosciences Holdings

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$1.5b
Net debt
positive
Cash
$672.6m
Shares outstanding
57.6m
Valuation (TTM | estimate)
P/E
11.1 | 10.8
P/S
2.5 | 2.4
EV/Sales
1.9 | 1.8
EV/FCF
5.1
P/B
2.4
Financial Health
Equity Ratio
66.0%
Return on Equity
22.1%
ROCE
22.9%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$825.9m | $862.6m
EBITDA
$249.5m | $278.4m
EBIT
$225.6m | $242.4m
Net Income
$185.7m | $188.2m
Free Cash Flow
$296.9m
Growth (TTM | estimate)
Revenue
21.1% | 20.7%
EBITDA
18.9% | 29.7%
EBIT
17.6% | 27.0%
Net Income
51.3% | 29.3%
Free Cash Flow
34.8%
Margin (TTM | estimate)
Gross
77.7%
EBITDA
30.2% | 32.3%
EBIT
27.3%
Net
22.5% | 21.8%
Free Cash Flow
36.0%
More
EPS
$3.2
FCF per Share
$5.2
Short interest
16.3%
Employees
268
Rev per Employee
$2.7m
Show more

Is Harmony Biosciences Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Harmony Biosciences Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Harmony Biosciences Holdings forecast:

14x Buy
82%
2x Hold
12%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Harmony Biosciences Holdings forecast:

Buy
82%
Hold
12%
Sell
6%

Financial data from Harmony Biosciences Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
826 826
21% 21%
100%
- Direct Costs 184 184
27% 27%
22%
642 642
20% 20%
78%
- Selling and Administrative Expenses 218 218
8% 8%
26%
- Research and Development Expense 174 174
40% 40%
21%
249 249
19% 19%
30%
- Depreciation and Amortization 24 24
33% 33%
3%
EBIT (Operating Income) EBIT 226 226
18% 18%
27%
Net Profit 186 186
51% 51%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Harmony Biosciences Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harmony Biosciences Holdings Stock News

Neutral
Business Wire
7 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant gastro-resistant (GR) formulation. With positive findings from both the pivotal BE and dosing optimization studies, Harmony is on track to submit a New Drug Application (NDA) for pitolisant GR in early 2026, t...
Neutral
Business Wire
12 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational, potentially best-in-class, orexin 2 receptor (OX2R) agonist being developed for the treatment of narcolepsy, idiopathic hypersomnia and other central disorders of hypersomnolence. The Phase 1 clini...
Neutral
Business Wire
13 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare Conference Location: Miami, FL Tuesday, December 2, 2025 8th Annual Evercore Healthcare Conference Location: Miami, FL Fireside Chat: Tuesday, December 2, 2025, at ...
More Harmony Biosciences Holdings News

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jeffrey Dayno
Employees 268
Founded 2017
Website www.harmonybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today